and IgM as well as cytokines such as interleukin 2, interleukin 4, and interleukin 6.16 Ursodeoxycholic acid may be beneficial in primary biliary cirrhosis, and we now have a clearer understanding of how it may work.Unfortunately, the nature of the disease makes it difficult to show definitive long term benefit.A meta-analysis of double blind placebo controlled data is planned and may be helpful.In comparison with previously suggested agents ursodeoxycholic acid is well tolerated and non-toxic.It should be used in patients with primary biliary cirrhosis except those with end stage disease, who should be considered for liver transplantation.
No takes yet. Share an insight, caveat, or question.
Ogilvie et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: